MDT
84.21
+0.41%↑
VEEV
227.67
+3.34%↑
A
106.91
+1.84%↑
WBA
11.03
+0.46%↑
CHE
546.34
-6.7%↓
MDT
84.21
+0.41%↑
VEEV
227.67
+3.34%↑
A
106.91
+1.84%↑
WBA
11.03
+0.46%↑
CHE
546.34
-6.7%↓
MDT
84.21
+0.41%↑
VEEV
227.67
+3.34%↑
A
106.91
+1.84%↑
WBA
11.03
+0.46%↑
CHE
546.34
-6.7%↓
MDT
84.21
+0.41%↑
VEEV
227.67
+3.34%↑
A
106.91
+1.84%↑
WBA
11.03
+0.46%↑
CHE
546.34
-6.7%↓
MDT
84.21
+0.41%↑
VEEV
227.67
+3.34%↑
A
106.91
+1.84%↑
WBA
11.03
+0.46%↑
CHE
546.34
-6.7%↓
24h
Current
Min
251.89
Max
259.28
Income | -31M -152M |
---|---|
Sales | 126M 1.1B |
Profit margin | -13.467 |
Recommendations | Strong Buy |
---|---|
12 Months Forecast | +28.53% upside |
Next Earnings | 7 May 2025 |
---|
Market Cap | 22B |
---|---|
Previous open | 253.18 |
Previous close | 255.76 |
Past performance is not a reliable indicator of future results.
29 Jan 2025, 15:59 UTC
ImmunityBio Shares Rise After Collaboration, Supply Agreement With BeiGene
DJ
Read
27 Nov 2024, 15:22 UTC
BeiGene Shares Up on EU Approval for Gastric, Esophageal Cancer Treatment
DJ
Read
21 Nov 2024, 14:45 UTC
Zymeworks Shares Rise 8.3% After Licensed Cancer Treatment Gets FDA OK
DJ
Read
22 Oct 2024, 18:39 UTC
Indaptus Therapeutics Shares Rise After Pact to Develop Cancer Treatment
DJ
Read
27 Feb 2025, 11:07 UTC
BeiGene Sees 2025 Rev $4.9B-$5.3B >ONC
DJ
Read
27 Feb 2025, 11:06 UTC
BeiGene 4Q Global BRUKINSA Rev of $828M >ONC
DJ
Read
27 Feb 2025, 11:06 UTC
BeiGene 4Q Loss/Shr 11c >ONC
DJ
Read
27 Feb 2025, 11:06 UTC
BeiGene 4Q Rev $1.13B >ONC
DJ
Read
12 Nov 2024, 11:01 UTC
BeiGene 3Q Loss/Shr 9c >BGNE
DJ
Read
12 Nov 2024, 11:01 UTC
BeiGene 3Q Rev $1B >BGNE
DJ
Read
7 Aug 2024, 10:05 UTC
BeiGene 2Q Loss/Shr $1.15 >BGNE
DJ
Read
7 Aug 2024, 10:04 UTC
BeiGene 2Q Rev $929M >BGNE
DJ
Read
8 May 2024, 10:02 UTC
BeiGene 1Q Loss/Shr 19c >BGNE
DJ
Read
8 May 2024, 10:01 UTC
BeiGene 1Q Loss $251.2M >BGNE
DJ
Read
8 May 2024, 10:01 UTC
BeiGene 1Q Rev $752M >BGNE
DJ
Read
Price change
By TipRanks
12 Months Forecast
Average 320.21 USD 28.53%
High 359.47 USD
Low 259 USD
Based on 13 Wall Street analysts offering 12 month price targets forBeiGene Ltd ADR - Dist in the last 3 months.
By TipRanks
Strong Buy
13 ratings
12
Buy
1
Hold
0
Sell
Based on 13 analysts giving stock ratings to BeiGene Ltd ADR - Dist in the past 3 months.
Selling and administration expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Operating profit
$